Document:

Exhibit
10.18

 

POINT
Biopharma Corp.

22 St. Clair Ave. East, Suite 1201, 

Toronto, ON M4T 2S3

 

Donna Husack

 

POINT Biopharma Corp. Employment Agreement

 

March 9, 2021

     

     

    

POINT
Biopharma Corp. Employment Agreement

 

to be effective as of and from

the Effective Date (as defined below)

 

PRIVATE
AND CONFIDENTIAL

 

Donna Husack

 

Dear Donna:

 

		Re:	Terms of Employment of Donna Husack (“you” or the “Employee”)
with POINT Biopharma Corp. (the “Company”)

 

This Agreement (as defined below) sets out the
terms and conditions of your employment by the Company and will constitute your employment agreement.

 

For and in consideration of the promises herein and
other valuable consideration, the parties agree as follows:

 

Article
1 Interpretation

 

		1.1	Definitions

 

For the purposes of this Agreement:

 

		1.1.1	“$” means CDN dollars.

 

		1.1.2	“Affiliate”
means with respect to a Person, any Person that, directly or indirectly, Controls, is Controlled by, or is under common Control
with such Person, including, without limitation, any partner, officer, director, or member of such Person and any venture capital
fund now or hereafter existing that is Controlled by or under common Control with one or more general partners or shares the same
management company or investment manager with such Person, and including any parent or subsidiary company of such Person.

 

		1.1.3	“Agreement” means this employment agreement
and the exhibits hereto.

 

		1.1.4	“Base Salary” shall have the meaning set
out in Section 3.2 (Base Salary).

 

		1.1.5	“Business” means the business of the Company
described in Exhibit 1.1.5.

    2 

     

    

		1.1.6	“Business Information” means all business information, including information regarding:

 

		.1	commercial strategies, business plans, business methods, corporate plans, management systems, finances, new business opportunities,
marketing or sales of any past, present or future product or service, including, without limitation, sales targets and statistics,
market share and pricing statistics, marketing surveys and plans, market research reports, sales techniques, price lists, discount
structures, advertising and promotional material;

 

		.2	financial information, compensation and investment arrangements, terms of agreements, financial structure, financial position,
financial results or other financial affairs, actual or proposed transactions or investments or other confidential information;
and

 

		.3	the name, address, telephone number, contact name and identity of each of the Key Contacts, the nature of their business operation,
and all confidential aspects of their business relationship or potential business relationship with the Company or any Affiliate
of the Company.

 

		1.1.7	“Cause” shall have the meaning set out in Section 6.6 (Termination by Company for Cause).

 

		1.1.8	“Change of Control” shall be deemed to have occurred if any of the following occurs after the Effective
Date and before the Termination Date:

 

		.1	any “person” or “group” (as such terms are defined below) is or becomes the “beneficial owner”
(as defined below, except that a “person” or “group” shall be deemed to have “beneficial ownership”
of all shares of capital stock or other equity interests if such person or group has the right to acquire such shares or interests,
whether such right is exercisable immediately or only after the passage of time), directly or indirectly, in a transaction or series
of related transactions, of shares of capital stock or other interests (including partnership interests) of the Company then outstanding
and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers
or similar supervisory positions (“Voting Stock”) of the Company representing more than fifty percent (50%)
of the total voting power of all outstanding classes of Voting Stock; or;

 

		.2	a sale of substantially all of the assets of the Company; or

    3 

     

    

		.3	the Company enters into a merger, reverse-merger, amalgamation, arrangement, consolidation or other form of business combination,
share exchange, reorganization, recapitalization, transfer or other similar transaction with another Person (whether or not the
Company the surviving entity) and as a result of such transaction (a) the members of the board of directors of the Company immediately
prior to such transaction constitute less than a majority of the members of the board of directors of the Company or such surviving
entity immediately following such transaction or (b) the Persons that beneficially owned, directly or indirectly, the shares of
Voting Stock of the Company immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of
Voting Stock of the Company representing at least a majority of the total voting power of all outstanding classes of Voting Stock
of the surviving entity immediately following such transaction.

 

Notwithstanding the foregoing, a Change of Control resulting
from a Financing or from corporate changes between Company Affiliates is deemed not to be a Change of Control for the purposes
of this Agreement.

 

		1.1.9	“Confidential Information” means all non-public
information, knowledge, or data pertaining to the business, affairs and technology of the Company or any Affiliate of the Company,
including:

 

		.1	Technical Information and Business Information;

 

		.2	your Work Product; and

 

		.3	information secured by the Company from Persons subject to an obligation of confidentiality;

 

and, in all cases, all copies and tangible embodiments
thereof, in whatever form or medium, all whether furnished or prepared before or after the Effective Date.

 

		1.1.10	“Control” or “Controls”
means, in relation to a corporation or a partnership, as the case may be:

 

		.1	the right to cast a majority of the votes that may be cast at a general meeting of the shareholders of a corporation;

 

		.2	the right to elect or appoint, directly or indirectly, a majority of the directors of a corporation;

 

		.3	to hold more than 50% of the interests of a partnership other than a limited partnership; and

 

		.4	to be the general partner of a limited partnership.

 

		1.1.11	“Effective
Date” shall have the meaning set out in Section 2.4

 

		1.1.12	“Financing” means capital secured for, and
accepted by, the Company including without limitation through any purchase, transfer or other disposition of any debt, equity or
other securities of the Company.

 

		1.1.13	“Inventions” means any and all discoveries,
developments, enhancements, improvements, concepts, formulas, processes, ideas, writings, whether or not reduced to practice, industrial
and other designs, patents, patent applications, provisional patent applications, continuations, continuations-in-part, substitutions,
divisionals, reissues, renewals, re-examinations, extensions, supplementary protection certificates or the like, trade secrets
or utility models, copyrights and other forms of intellectual property including all applications, registrations and related foreign
applications filed and registrations granted thereon.

    4 

     

    

		1.1.14	“Key Contacts” means the actual and potential: licensors, licensees, sublicensees, collaborators, partners,
investors, shareholders, acquirers, lenders or merger candidates, suppliers and customers of the Company or any Affiliate of the
Company.

 

		1.1.15	“Notice Period” shall have the meaning set out in Section 6.1 (Termination by Employee)

 

		1.1.16	“Objectives” shall have the meaning set out in Section 3.3 (Annual Bonus)

 

		1.1.17	“Option Agreement” shall have the meaning set out in Section 3.5 (Stock Options).

 

		1.1.18	“Person” means any individual, partnership, joint venture, syndicate, sole proprietorship, company or corporation
with or without share capital, trust, trustee, executor, administrator, or other legal personal representatives, regulatory body
or agency, government or governmental agency, authority or entity howsoever designated or constituted.

 

		1.1.19	“Technical Information” means all technical information of the Company or any Affiliate of the Company,
including information regarding knowledge or data of an intellectual, technical, scientific or industrial nature, including compositions
of matter, techniques, specifications, standards, technical data, uses of matter, practices, methods, computer data, scientific
strategies and concepts, clinical and regulatory strategies and concepts, test data, research data, analytical and quality control
data, formulation data, manufacturing data, development information, filings for the protection of intellectual property protection,
drawings, specifications, designs, plans, proposals, reports, formulas, compilations, research data and manuals.

 

		1.1.20	“Term of Employment” means the period from the Effective Date until the date on which your employment with
the Company ceases in accordance with Article 6.

 

		1.1.21	“Termination Date” shall have the meaning set out in Section 6.7.

 

		1.1.22	“Vice President Human Resources” shall
                                         have the meaning set out in Section 2.1 (Position and Duties).

 

		1.1.23	“Work Product” means any and all works
                                         of authorship, including

 

		.1	all Inventions and possible Inventions relating to the Company’s Business resulting from any work performed by you for
the Company that you may invent or co-invent during your involvement in any capacity with the Company, except those Inventions
invented by you entirely on your own time that do not relate to the Company’s Business or do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, by you from or through your
involvement in any capacity with the Company; and

 

		.2	all Technical Information and Business Information resulting from any work performed by you for
the Company; and includes all analyses, compilations, studies, reports or other documents prepared by you based upon or including
any such information, data or knowledge of the Company or any Affiliate of the Company.

    5 

     

    

Article
2 Position, Duties and Service

 

		2.1	Position and Duties

 

You will be employed by and will serve the Company, having the
duties and functions customarily performed by, and having all responsibilities customary to, Vice President Human Resources, including
those described in Exhibit 2.1.

 

You will report directly to the Chief Executive Officer of the
Company. The rights of the Company as provided in this Agreement may be exercised on behalf of the Company only by the Chief Executive
Officer, Board, or by a committee or person expressly designated for such purposes by the Board.

 

		2.2	Changes to Duties

 

Your duties and functions pertain to the Company or any Affiliate
of the Company and may be varied or added to from time to time by the Chief Executive Officer and the Board in its discretion.

 

		2.3	Service to the Company

 

During the Term of Employment, you will:

 

		2.3.1	well and faithfully serve the Company, at all times act in the best interests of the Company, and, to the extent necessary
to discharge the responsibilities assigned to you hereunder, you will use your best efforts to perform faithfully and efficiently
such responsibilities;

 

		2.3.2	apply your skill and experience to the performance of your duties in such employment;

 

		2.3.3	comply with all policies and procedures from time to time formulated by the Company;

 

		2.3.4	devote all of your working time, attention and energies to the business and affairs of the Company; and

 

		2.3.5	not, without the prior approval of the Company, carry on or engage in any other business or occupation or become a director,
officer, employee or agent of or hold any position or office with any other company, firm or person other than the Company, except
as disclosed in Exhibit 2.3.5 or as a volunteer for a non-profit organization, engaging in civic, religious, educational or other
community activities, or maintaining personal investments or a personal holding company, provided that such activities do not materially
interfere with the performance of your duties under this Agreement.

    6 

     

    

		2.4	Term

 

The terms and conditions of this Agreement shall
have effect as and from March 9, 2021 (the “ Effective Date”)
and throughout the Term of Employment. You agree that your service with any prior employer shall not be included in the calculation
of the length or period of your employment with the Company, except as may be required by the Ontario Employment
Standards Act, 2000 and the regulations enacted thereunder, each as amended (the “ESA”).

 

Article
3 Compensation Generally

 

		3.1	No Other Compensation or Benefits

 

You will be compensated as set out in this Article. Unless otherwise
agreed by the parties in writing, you expressly acknowledge and agree that you will not be entitled by reason of your employment
by the Company or by reason of any termination of such employment, to any remuneration, compensation, severance, damages or benefits
other than as expressly set forth in this Agreement, the Option Agreement and as expressly required by applicable employment standards
legislation, including the ESA.

 

		3.2	Base Salary

 

During the Term of Employment, the Company will pay you an annual
base salary (the “Base Salary”) at the rate
of $215,000 per annum, payable on a bi-weekly basis (26 pay periods), subject to applicable withholdings and deductions. The Base
Salary will be reviewed on an annual basis, or as otherwise determined by the Company. Any merit increases are subject to the approval
and discretion of the Board. As an employee whose work is supervisory and/or managerial in character (although you may perform
non-supervisory and/or non-managerial tasks on an irregular or exceptional basis), you are not eligible to be paid overtime pay
or to take lieu time, except as may be specifically required by the ESA.

 

		3.3	Annual Bonus

 

An annual bonus will be in effect, and is based on you meeting
established performance objectives and due 30 days after the board has approved the corporate yearend financial statements.
During the Term of Employment, you will be eligible for a target cash bonus of up to twenty-five percent (25%) of your Base Salary
under this Agreement if the Board (or the Company’s Compensation Committee), in its sole discretion, determines that the
Company has met its short-term and long-term business performance objectives and that you have met your personal performance objectives
(together, the “ Objectives”), which Objectives
will be established on an annual basis by the CEO and Board (or the Company’s Compensation Committee) in consultation with
you. Payment of the performance bonus (less all applicable statutory deductions by the Company) will be made to you once approved
by the Board (or Company’s Compensation Committee), and within 30 days after the Board has approved the corporate yearend
financial statements, provided that, except as otherwise set out in this Agreement, at the time of such approval, you hold current
active employment status with the Company. You acknowledge that participation in any incentive or bonus plan during any one year
confers no rights upon you or any obligations on the Company to continue the plan or entitle you to participate in the plan in
succeeding years. Except only as expressly required by applicable employment standards legislation, including the ESA, no incentives
or bonuses will be paid or are payable to you following the Termination Date and you waive any entitlement to damages in lieu thereof
whether pursuant or attributable to any common law notice period or otherwise.

    7 

     

    

		3.4	Signing Incentives

 

Subject to the approval of Board of Point BioPharma Inc. (the
 “Parent”), you will be granted a nonqualified option to purchase 2,500 shares of the shares of Parent (the
 “Option”), subject to the terms and conditions applicable to options granted under the Equity Incentive Plan
and the stock option agreement (together with the Equity Incentive Plan, the “Option Agreement”). The exercise
price per share of the Option will be equal to the fair market value per share of the Parent’s Common Stock on the date
the Option is granted, as determined by the Parent Board.

 

		3.5	Stock Options in the Event of a Change of Control

 

Subject to the terms and conditions of the Option Agreement,
in the event that as of the date of a Change of Control, you hold unvested stock options that had been granted to you under the
Option Agreement, such unvested stock options shall immediately vest and shall be exercisable in accordance with the terms and
conditions of the Option Agreement.

 

		3.6	Reimbursement for Expenses

 

As of the Effective Date, the Company agrees to reimburse you
for reasonable travelling and other expenses actually and properly incurred in the course of employment. For all such expenses,
you will be required to keep proper accounts and to furnish such statements and vouchers to the Company.

 

		3.7	Vacation

 

During the Term of Employment, you will be entitled to twenty
(20) working days’ vacation, pro-rated for any partial year of employment. The Company reserves the right to request that
vacations be scheduled so as not to conflict with business needs. While you must take at least your minimum statutory entitlement
to vacation each year, any unused vacation balance remaining at calendar year end in excess of minimum statutory vacation entitlements
may be carried over into the subsequent calendar year to a cumulative maximum not exceeding forty (40) working days of vacation.
Subject to applicable employment standards legislation, including the ESA, any vacation carried over in excess of forty (40) days
will be forfeited.

 

		3.8	Benefits

 

During the Term of Employment, the Company will provide for
group health, drugs, dental, vision and life insurance benefits through a mutually agreeable arrangement as is made available to
its executives from time to time. You hereby acknowledge that coverage under any benefit plan, or alternate plan arrangement as
agreed upon in effect from time to time is subject to availability and other requirements of the applicable insurer and that the
components of the benefits plan may be amended, modified or terminated from time to time by the Company in its sole discretion,
and that this may include terminating or changing carriers.

    8 

     

    

Article
4 Intellectual Property Rights

 

		4.1	Obligation of Confidentiality

 

You understand and agree that in the course of your employment
with the Company, both before and after the Effective Date, you have obtained and will obtain knowledge of Confidential Information.
You agree that unless the Company otherwise agrees in writing or except as required by law or disclosed pursuant to a confidential
disclosure agreement executed by the Company and the recipient:

 

		4.1.1	you will keep all Confidential Information learned or acquired by you, disclosed to you or developed by you, as a result of
or in connection with or during the course of your employment by the Company, whether before or after the Effective Date, strictly
confidential;

 

		4.1.2	all Confidential Information shall, as between you and the Company, be and remain the property of the Company; and

 

		4.1.3	you will not at any time, during or after your employment with the Company, disclose any Confidential Information to any Person
other than the Company, or use any Confidential Information for the benefit of any Person other than the Company.

 

The above obligations with respect to Confidential Information
shall not apply to Confidential Information which has become available to the general public through no fault of your own.

 

		4.2	Disclosure of Work Product

 

You agree to promptly and fully inform the Company of all of
your Work Product, whether or not patentable, throughout the course of your involvement, in any capacity, with the Company or any
Affiliate of the Company, whether or not developed before or after your execution of this Agreement. On your ceasing to be employed
by the Company, you will immediately deliver up to the Company all of your Work Product. You further agree that all of your Work
Product shall at all times be the Confidential Information of the Company.

 

		4.3	Assignment of Rights

 

You will assign, and do hereby assign, to the Company or, at
the option of the Company and upon notice from the Company, to the Company’s designee, your entire right, title and interest
in and to all of your Work Product and all other rights and interests of a proprietary nature in and associated with your Work
Product, including all patents, copyrights, trademarks, and applications filed therefore and other registrations granted thereon.
To the extent that you retain or acquire legal title to any such rights and interests, you hereby declare and confirm that such
legal title is and will be held by you only as trustee and agent for the Company. You agree that the Company’s rights hereunder
shall attach to all of your Work Product, notwithstanding that it may be perfected or reduced to specific form after you have terminated
your relationship with the Company. You further agree that the Company’s rights hereunder shall extend to every country of
the world.

    9 

     

    

		4.4	Moral Rights

 

You agree to, and do hereby waive, in whole all moral rights
and agree never to assert any moral rights which you may have in your Work Product, including, without limitation, the right to
the integrity of such Work Product, the right to be associated with the Work Product, the right to restrain or claim damages for
any distortion, mutilation or other modification or enhancement of the Work Product and the right to restrain, the use or reproduction
of the Work Product in any context and in connection with any product, service, cause or institution and you further confirm that
the Company may use or alter any such Work Product as the Company sees fit in its absolute discretion.

 

		4.5	Goodwill

 

You hereby agree that all goodwill you have established or may
establish with Key Contacts relating to the business or affairs of the Company or any Affiliate of the Company, both before and
after the Effective Date, shall, as between you and the Company, be and remain the property of the Company exclusively, for the
Company to use, alter, vary, adapt and exploit as the Company shall determine in its discretion.

 

		4.6	Assistance

 

You hereby agree to assist the Company, at the Company’s
request and expense, both during your Term of Employment and at all times after termination of your Term of Employment for any
reason whatsoever, in:

 

		4.6.1	making patent applications for your Work Product, including instructions to lawyers and/or patent agents as to the characteristics
of your Work Product in sufficient detail to enable the preparation of a suitable patent specification, to execute all formal documentation
incidental to an application for letters patent and to execute assignment documents in favor of the Company for such applications;

 

		4.6.2	making applications for all other forms of intellectual property registration relating to your Work Product;

 

		4.6.3	prosecuting and maintaining the patent applications and other intellectual property relating to your Work Product; and

 

		4.6.4	registering, maintaining and enforcing the patents and other intellectual property registrations relating to your Work Product.

 

		4.7	Assistance with Proceedings

 

You further agree to lend such assistance as you can, at the
Company’s request and expense, in connection with any enforcement of the Company’s intellectual property rights or
defense to an allegation of infringement of another Person’s intellectual property rights, invalidity proceedings respecting,
opposition to, or intervention regarding any applications for letters patent, copyright or trademark or other proceedings relating
to intellectual property or applications for registration thereof.

    10 

     

    

Article
5 Conflicts and Restrictive Covenant

 

		5.1	Disclosure of Conflicts of Interest

 

During your employment with the Company, you will promptly,
fully and frankly disclose to the Company in writing:

 

		5.1.1	the nature and extent of any interest you have or may have, directly or indirectly, in any contract or transaction or proposed
contract or transaction of or with the Company or any Affiliate of the Company or any Key Contact;

 

		5.1.2	every office you may hold or acquire, and every property you may possess or acquire, whereby directly or indirectly, a duty
or interest might be created in conflict with the interests of the Company or any Affiliate of the Company, or your duties and
obligations under this Agreement; and

 

		5.1.3	the nature and extent of any conflict referred to in Sections 5.1.1 and 5.1.2.

 

		5.2	Avoidance of Conflict of Interest

 

You acknowledge that it is the policy of the Company that all
interests and conflicts of the sort described in Section 5.1 (Disclosure of Conflicts of Interest) be avoided, and you agree to
comply with all policies and directives of the Company from time to time regulating, restricting or prohibiting circumstances giving
rise to interests or conflicts of the sort described in Section 5.1. During your employment with the Company, you shall not enter
into any agreement, arrangement or understanding with any other Person that would in any way conflict or interfere with this Agreement
or your duties or obligations under this Agreement or that would otherwise prevent you from performing your obligations hereunder,
and you represent and warrant that you have not prior to the Effective Date entered into any such agreement, arrangement or understanding.

 

		5.3	Restrictive Covenant

 

During the Term of Employment and for a period of 6 months thereafter
for Sections 5.3.1 and 5.3.2, and a period of 18 months thereafter for Section 5.3.3, regardless of the reason for such termination,
you will not, either alone or in partnership or in conjunction with any Person, whether as principal, agent, employee, director,
officer, shareholder, consultant or in any capacity or manner whatsoever, whether directly or indirectly:

 

5.3.1
carry on or be engaged in, or advise, or give financial assistance to, any business, enterprise or undertaking within Canada that:

 

.1 is involved in the business or in the sale, distribution,
development or supply of any product or service that is the same as or substantially similar to the products or services offered
by the Company as at the date of the termination of your employment (the “Termination Date”); or

 

.2 competes in a substantial or material way with
the Company with respect to any aspect of the Business as at the Termination Date; provided, however, that the foregoing will not
prohibit you from acquiring, solely as an investment and through market purchases, securities of any such enterprise or undertaking
which are publicly traded, so long as you are not part of any control group of such entity and such securities, which if converted,
do not constitute more than 5% of the outstanding voting power of that entity;

    11 

     

    

5.3.2 agree to be employed by any Person that was a Key
Contact as at the Termination Date (but in any case, with whom you have had business contact in the course of your employment with
the Company during the two years prior to the Termination Date ) for any business purpose that is competitive with the Business
in any substantial or material way; or make use of any list or proprietary information of or relating to such Key Contacts for
the purpose of competing with the Company; or be involved in the sale to, solicitation of or servicing of any such Key Contact
where such sale, solicitation or servicing is with respect to services or products which are the same or substantially similar
to or which compete with products or services sold or provided by the Company as at the Termination Date; or otherwise attempt
to interfere with or damage the Company’s business relationship with any such Key Contact; or

 

5.3.3 solicit, divert, entice or take away from the Company
or any Affiliate of the Company with whom you have been actively engaged in business contact in the course of your employment with
the Company in the 18 months prior to the Termination Date or in respect of whom you acquired confidential or proprietary information
during the course of your employment with the Company that the Company has a reasonable need to protect against (a “Protected
Affiliate”), or attempt to do so or solicit for the purpose of doing so, any business of the Company or any Protected Affiliate
of the Company, or any Person that was an employee or contractor of the Company or any Protected Affiliate (but in any case, with
whom you have had business contact in the course of your employment with the Com during the 18 months prior to the Termination
Date) to terminate, discontinue or alter to the detriment of the Company, his, her or its employment or engagement relationship
with the Company or its Protected Affiliates or otherwise attempt to interfere with or damage the Company’s relationship
with any such person.

 

5.4
Provisions Reasonable

 

You hereby acknowledge and agree that:

 

5.4.1 the Company has a material interest in preserving
the relationships it has developed with its Key Contacts against impairment by competitive activities of a former employee;

 

5.4.2 during the course of your employment by the Company,
you will acquire knowledge of, and you will come into contact with, initiate and establish relationships with Key Contacts, and
that in some circumstances you may be the senior or sole representative of the Company or any Affiliate of the Company dealing
with such Persons; and

 

5.4.3 in light of the foregoing, the provisions of Section
5.3 (Restrictive Covenant) are reasonable and necessary for the proper protection of the business, property and goodwill of the
Company and the Business and any Protected Affiliate and you further agree that these restrictions and your agreement to them are
of major importance to the Company, which would not employ or continue to employ you if you did not agree to them.

 

5.5 Right to Use Employee’s Name and Likeness

 

During the Term of Employment, you hereby grant to the Company
the right to use your name, likeness and/or biography in connection with services performed by you under this Agreement and in
connection with the advertising or exploitation of any project with respect to which you perform services for the Company.

    12 

     

    

Article
6 Termination

 

		6.1	Termination by Employee

 

You may resign from your position at any time, but only by giving
the Company at least 30 days prior written notice of the effective date of your resignation (the “Notice
Period”). On the giving of any such notice, the Company may accelerate your resignation, in lieu of the Notice
Period or any part thereof, by notice in writing to you and payment to you of any compensation and continuation of benefits due
to you for the balance of the 30-day Notice Period pursuant to this Agreement, less applicable statutory deductions. You agree
that such acceleration of your resignation shall not constitute termination of your employment by the Company.

 

		6.2	Termination by Company Without Cause

 

The Company may terminate your employment at any time without
Cause (as defined below) in accordance with the terms set out in this Agreement and by giving you written notification of termination.
In the event that your employment is so terminated, you will have the common law duty to mitigate your damages.

 

		6.3	Consequences of Termination Without Cause Unrelated to a Change of Control

 

Subject to Section 6.4, on the giving of any notice referred
to in Section 6.2, the Company shall provide you with the greater of either (i) 3 months’ Base Salary, bonus (3.3), in addition
to 1 month for every year of service (or part thereof) to the company upon and effective at 3 years of employment, or (ii) the
minimum notice or pay in lieu of notice and severance pay, if applicable, that is expressly required by applicable employment standards
legislation, including the ESA. In the case of either Section 6.3(i) or (ii), your participation in Company benefits plans will
be continued for only the minimum period expressly required by applicable employment standards legislation, including the ESA.
Other than as set out in this Section and Section 6.7, you will not be entitled to any additional notice, pay in lieu of notice,
severance or other payments whether pursuant to the common law or otherwise upon termination of your employment without Cause unrelated
to a Change of Control pursuant to this Section 6.3.

 

		6.4	Consequences of Termination Without Cause After a Change of Control

 

On the giving by the Company to you of the written notice referred
to in Section 6.2: (i) at the same time as, or within the twelve (12) month period following, the consummation of a Change of Control,
or (ii) within the thirty (30) day period prior to the date of the consummation of a Change of Control where such Change of Control
was under consideration by the Board at the time of your termination, then the following terms apply in substitution of the compensation
and benefits referred to in Section 6.3 above:

 

		6.4.1	the Company shall provide you with the greater of either (i) 6 months’ Base Salary and bonus (3.3), in addition to 1
month for every year of service (or part thereof) to the company, upon and effective at 3 years of employment, or (ii) the minimum
notice or pay in lieu of notice and severance pay, if applicable, that is expressly required by applicable employment standards
legislation, including the ESA, plus in the case of either Section 6.4.1(i) or (ii), your participation in Company benefits plans
will be continued for only the minimum period expressly required by applicable employment standards legislation, including the
ESA; and

    13 

     

    

		6.4.2	as set out in and subject to the terms of Section 3.5 above, as of the date of the consummation of the Change of Control, any
unvested stock options granted to you under the Option Agreement will vest and be exercisable in accordance with the terms and
conditions of this Option Agreement.

 

Other than as set out in this Section and Section 6.7 below,
you will not be entitled to any additional vesting, notice, pay in lieu of notice, severance or other payments whether pursuant
to the common law or otherwise upon termination of your employment without Cause after a Change of Control pursuant to this Section
6.4.

 

		6.5	Termination in the Event of Death

 

Your employment shall terminate immediately upon your death
and the Company shall pay your estate any amounts which may be due and remaining unpaid at the time of the termination of employment,
in accordance with applicable employment standards legislation, including the ESA.

 

		6.6	Termination by Company for Cause

 

Notwithstanding any other provision in this Agreement, the
Company may at any time summarily terminate your employment, without any obligation to provide notice of pay in lieu of notice,
for “Cause”, in which case you will only be entitled to receive such minimum compensation, benefits continuation,
and any other entitlements as are expressly required by applicable employment standards legislation, including the ESA. In this
Agreement, “Cause” means any of the following:

 

		6.6.1	commission of theft, embezzlement, fraud, obtaining funds or property under false pretenses or similar acts of misconduct with
respect to the property of the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers,
employees or contractors;

 

oral or written representations made by you to the Company
or any Affiliate of the Company with the intent to deceive or mislead; commission of an act of malfeasance, dishonesty or breach
of trust against the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers, employees
or contractors, including a breach by you of any of your covenants or obligations under Section 5.1 (Disclosure of Conflicts of
Interest), Section 5.2 (Avoidance of Conflicts of Interest) or Section 5.3 (Restrictive Covenant);

 

		6.6.2	the entering of a guilty plea by you or your conviction for a serious criminal offence which impacts adversely on the Company
or any Affiliate of the Company;

 

		6.6.3	repeated and continued failure to fulfill your duties or obligations of employment or your breach of any material obligations
and covenants under this Agreement. Termination for such “Cause” shall only occur if you have been given written notice
of such failure to fulfill your duties or obligations and you have been given an opportunity to correct such behavior;

    14 

     

    

		6.6.4	the termination of your employment with POINT Biopharma Corp. other than a termination pursuant to section 6.2; or

 

		6.6.5	any other misconduct or omission that amounts to just cause for summary dismissal at common law. In the event the Company dismisses
you for cause pursuant to this Section 6.6 and, subsequently, a court or arbitrator rules that the Company did not have cause,
you hereby agree that you will only be entitled to damages in an amount equal to the compensation that would have been due to you
had the Company terminated your employment pursuant to Section 6.3 (Consequences of Termination Without Cause), less any amounts
earned by you in mitigation.

 

		6.7	Termination Date and Full Satisfaction

 

“Termination Date” means the earlier of: (i) the
date on which you are notified in writing by the Company of the termination of your employment for any reason, and (ii) the date
on which you notify the Company of your resignation from employment for any reason, but in any case, without regard to any payment
or notice period to which you might then be entitled.

 

It is agreed that as a result of the termination of your employment,
for any reason, you shall not be entitled to any notice, fee, salary, severance or other payments, benefits or damages in excess
of what is specified or provided for in Section 6.1 (Termination by Employee), Section 6.3 (Consequences of Termination Without
Cause Unrelated to a Change of Control), Section 6.4 (Consequences of Termination Without Cause After a Change of Control) and
Section 6.6 (Termination by Company for Cause), whichever is applicable, except that you shall remain entitled to receive all salary
and other amounts, if any, which are then due and owed to you as of the Termination Date, in addition to any accrued but unpaid
vacation pay and any other minimum entitlements expressly required to be provided to you by (and any such minimum entitlements
shall be calculated in accordance with) applicable employment standards legislation, including the ESA. Payment of any amounts
pursuant to Section 6.1 (Termination by Employee), Section 6.3 (Consequences of Termination Without Cause Unrelated to a Change
of Control), Section 6.4 (Consequences of Termination Without Cause After a Change of Control), and Section 6.6 (Termination by
Company for Cause) shall be subject to the withholding of all applicable statutory deductions by the Company. You will be required
to execute a standard release of claims document in a form satisfactory to the Company in order to receive any payments in excess
of those required by applicable employment standards legislation, including the ESA.

    15 

     

    

Article
7 General

 

		7.1	Agreement Confidential

 

Both parties shall keep the terms and conditions of this Agreement
confidential except as may be required to enforce any provision of this Agreement or as may otherwise be required by any law, regulation
or other regulatory or securities requirement.

 

		7.2	Binding Effect

 

This Agreement shall be binding upon and inure to the benefit
of the Company and its successors and assigns. Your rights and obligations contained in this Agreement are personal and such rights,
benefits and obligations shall not be voluntarily or involuntarily assigned, alienated or transferred, whether by operation of
law or otherwise, without the prior written consent of the Company. This Agreement shall otherwise be binding upon and inure to
the benefit of your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, legatees
and permitted assigns.

 

		7.3	Counterparts

 

This Agreement may be executed in several counterparts (including
by fax or electronic transmission), each of which when so executed shall be deemed to be an original and shall have the same force
and effect as an original but such counterparts together shall constitute but one and the same instrument.

 

		7.4	Entire Agreement

 

The terms and conditions of this Agreement are in addition to
and not in substitution for the obligations, duties and responsibilities imposed by law on employees of corporations generally,
and you agree to comply with such obligations, duties and responsibilities. Except as otherwise provided in this Agreement, this
Agreement constitutes the entire agreement between you and the Company and supersedes all prior negotiations, proposals and agreements,
whether oral or written, with respect to the subject matter hereof, and may only be varied by further written agreement signed
by you and the Company. You further acknowledge and agree that you have not relied on any representation made by the Company, or
any of its employees or agents, except as specifically set out in this Agreement.

 

		7.5	Further Assurances

 

Each of the parties hereto will, on demand by the other party
hereto, execute and deliver all such further documents and instruments and do all such further acts and things as the party may
either before or after the execution and delivery of this Agreement reasonably request to evidence, carry out and give full effect
to the terms, conditions, intent and meaning of this Agreement.

 

		7.6	Governing Law

 

This Agreement shall be construed and enforced in accordance
with and be governed by and interpreted in accordance with the laws of the Province of Ontario and the law of Canada applicable
therein, without regard to the principles of conflicts of law. The courts of Ontario (and the Supreme Court of Canada, if necessary)
shall have exclusive jurisdiction to hear and determine all disputes arising hereunder, and each of the parties hereto irrevocably
attorns to the jurisdiction of said courts.

    16 

     

    

		7.7	Independent Legal Advice

 

You acknowledge and agree that the Company has given you the
opportunity to seek, and has recommended that you obtain, independent legal advice with respect to the subject matter of this Agreement
and, further, you hereby represent and warrant to the Company that you have either sought independent legal advice or have waived
your right to obtain such advice.

 

		7.8	Injunctive Relief

 

You acknowledge and agree that any breach or threatened breach
of any of the provisions of, Section 5.1 (Disclosure of Conflicts of Interest), Section 5.2 (Avoidance of Conflicts of Interest),
or Section 5.3 (Restrictive Covenant) could cause irreparable damage to the Company, that such harm could not be adequately compensated
by the Company’s recovery of monetary damages, and that in the event of a breach or threatened breach thereof, the Company
shall have, in addition to any and all remedies at law or in equity, the right to seek an injunction, specific performance or other
equitable relief as well as any equitable accounting of all your profits or benefits arising out of any such breach. It is further
acknowledged and agreed that the remedies of the Company specified in this Section 7.8 are in addition to and not in substitution
for any rights or remedies of the Company at law or in equity and that all such rights and remedies are cumulative and not alternative
and that the Company may have recourse to any one or more of its available rights or remedies as it shall see fit.

 

		7.9	Non-Disparagement

 

You shall not, directly or indirectly, make any disparaging
comments or criticisms (whether of a professional or personal nature) to any Person regarding the Company, any Affiliate of the
Company, the Key Contacts, or their respective directors, officers, employees or contractors (or the terms of any agreement or
arrangement of the Company) or regarding your relationship with the Company or any termination of such relationship which, in each
case, are reasonably expected to result in material damage to the business or reputation of the Company, any Affiliate of the Company,
a Key Contact, or any of their respective directors, officers, employees or contractors.

 

Upon termination of your employment for any reason whatsoever,
you agree that you will not, directly or indirectly, verbally or in writing, criticize, disparage, speak negatively of, or make
any harmful statement about the Company, or its employees, products or services (including but not limited to on any social media
or on Glassdoor or similar websites, blogs, etc.). Further, you agree that you will immediately cease to represent yourself as
being in any way connected with, or interested in, the Company, and will immediately update any social media (including any blogs
or social networking sites, including but not limited to LinkedIn) to reflect this.

    17 

     

    

		7.10	Notice

 

Any notice or other communication required or contemplated to
be given hereunder must be in writing and shall be deemed effective when personally delivered or on the day following the sending
when sent by facsimile transmission, addressed to the appropriate party as set forth below:

 

If to the Employee:

 

Donna
Husack

 

If to the Company:

 

POINT
Biopharma Corp.

22 St. Clair Ave. East, Suite 1201, 

Toronto, ON M4T 2S3

 

Attention: Bill Demers, CFO

 

		7.11	Publicity

 

You shall not, without the prior written consent of the Company,
make or give any public announcements, press releases or statements to the public or the press regarding your Work Product or any
Confidential Information.

 

		7.12	Severability

 

If any provision of this Agreement is determined to be void,
illegal or unenforceable, such provision will be construed to be separate and severable from this Agreement and will not impair
the validity, legality or enforceability of any other provision of this Agreement and the remainder of this Agreement will continue
to be binding on the parties hereto as if such provision had been deleted.

 

It is not the Company’s intention to attempt to contract
out of its obligations or your minimum entitlements under applicable employment standards legislation, including the ESA. Therefore,
notwithstanding anything stated or unstated in this Agreement or in the Company’s policies and procedures, you will not,
under any circumstances, receive anything less than your full entitlements under applicable employment standards legislation, including
the ESA. Any provision of this Agreement or such policies and procedures that provides for anything less than such entitlements
shall be deemed to be replaced by the applicable minimum standard under applicable employment standards legislation, including
the ESA.

 

		7.13	Surviving Obligations

 

Upon termination of this Agreement for any reason, any obligations
which by their terms or nature, must extend beyond the date of termination to be effective shall survive termination of this Agreement.
Without limiting the foregoing, your obligations under Section 5.3 (Restrictive Covenant), Section 5.4 (Provisions Reasonable),
Article 6 (Termination) and Article 7 (General) shall survive and remain in full force and effect following the termination of
this Agreement.

    18 

     

    

		7.14	Waiver

 

Any waiver of any breach or default under this Agreement shall
only be effective if made in writing, signed by the party against whom the waiver is sought to be enforced, and no waiver shall
be implied by any other act or conduct or by any indulgence, delay or omission. Any waiver shall only apply to the specific matter
waived and only in the specific instance in which it is waived.

 

		7.15	Acceptance

 

If the foregoing terms and conditions are acceptable to you,
please indicate your acceptance of and agreement to the terms and conditions of this agreement by signing below on this letter
and on the enclosed copy of this letter in the space provided and by returning the enclosed copy so executed to us. Your execution
and delivery to the Company of the enclosed copy of this letter will create a binding agreement between us.

 

Yours truly,

POINT Biopharma Corp.

 

Per: /s/ Joe McCann

Authorized Signatory

 

Joe McCann, CEO

 

Acknowledged and Agreed:

I acknowledge that I have had sufficient time to thoroughly review this agreement and obtain the advice that I deem appropriate
regarding its terms and conditions. I have read, understand and voluntarily accept employment with POINT Biopharma Corp. on the
terms and conditions set out above.

 

	March 9, 2021	 	      /s/ Donna Husack	 
	Date	 	Donna Husack	 

    19 

     

    

Exhibit
1.1.5: Description of the Business

 

The Company is a clinical stage pharmaceutical company focused
on the development and commercialization of radiotherapeutics and theranostic products. The company will compete in therapeutic
categories related to the use of radiotherapeutics and theranostic products in oncology.

    20 

     

    

Exhibit
2.1: Description of Duties – Vice President Human Resources

 

The Vice President Human Resources reports directly to the Chief
Executive Officer.

 

		1.1.	Top executive responsible for overseeing the overall human resources function in an independent corporation on a global basis.

		1.2.	Responsible for overseeing the planning, development, implementation and administration of the company’s human resources
strategies and programs, including succession planning, compensation and benefits, recruitment, training, leadership development,
talent management, performance management and employee relations programs.

		1.3.	Responsible for establishing long-range human resource strategies and practices for the organization to meet specific business
objectives.

		1.4.	Ensures business processes comply with regulatory and legal requirements globally to minimize risk to the organization.

		1.5.	May provide internal leadership coaching to members of the CEO’s executive staff and interacts with executive-level management
on a peer basis.

		1.6.	May have responsibility for facilities/real estate management.

 

Exhibit 2.3.5: Permitted External Roles

 

		1.	Continue on the Board of Pharmaceutical Science Group (PSG)

    21Exhibit 10.19

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED
AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL
AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

SUPPLY AGREEMENT (“Supply Agreement”)
effective as of the date of last signing (“Effective Date”) between POINT Biopharma Corporation having a place of business
at 22 St. Clair Ave. East, Suite 1201, Toronto, Ontario M4T 2S3 (“POINT”), and Centre for Probe Development and Commercialization
having a place of business at McMaster University, Nuclear Research Building A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S
4K1, (“CPDC”), (together the “Parties” and each a “Party”). This document defines the terms and conditions
under which CPDC will provide POINT the Product outlined in this Supply Agreement.

 

	1.	Product:
	 	 
	1.1.	 Lu-177-PNT2002 (the “Product”)
	 	 
	1.2.	The specifications for the Product are further defined in QC-SPEC-0139.
	 	 
	2.	Definitions

 

As used herein, the following terms shall have the following meanings:

 

	2.1.	“Batch” shall mean a single production, testing and release of Product according to the approved and validated processes.
	 	 
	2.2.	 “Calendar Quarter” shall mean a period of 3 months starting the first day of either one of the flowing months, January,
April, July, October.
	 
	2.3.	 “Calendar Year” shall mean a 12 month period starting on January 1st and ending on December 31st.
	 
	2.4.	 “Clinical Phase” shall mean the period during which human studies involving the Products are performed for the purpose of
evaluating the safety, efficacy and appropriate dose ranges of Product (“Clinical Trials”), to secure marketing approval
from a Regulatory Authority.
	 
	2.5.	 “Commencement Date” shall mean the date on which the first Production Order is placed by POINT.
	 
	2.6.	 “Commercial Phase” shall mean the period of supply of a Product in a particular country commencing after marketing authorization
has been received in that country from a Regulatory Authority.
	 
	2.7.	 “Current Good Manufacturing Practices” or “cGMP(s)” shall mean the standards required by the Regulatory Authority
for the manufacturing, testing and quality control of pharmaceutical materials, which practices are current on the Effective Date of
the Agreement and may be supplemented, amended or modified by such regulatory authority from time to time.
	 
	2.8.	 “Filling, Packaging & Labelling Fees” shall mean the portion of the Unit Fees for Filling, Packaging and Labelling,
as defined in Schedule 1.
	 
	2.9.	“Dose” shall mean Unit.
	 
	2.10.	 “Precursor” shall mean the drug substance starting material required to produce Product.
	 
	2.11.	“Process” shall mean a GMP manufacturing process/procedure for producing the Product, including cold preparations, radiolabelling,
formulation, dispensing, in process manufacturing controls, and all applicable testing and evaluation suitable to meet regulatory requirements
for use of the Product in clinical trials.

 

	Page 1 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

 

 

	2.12.	“Production Order” shall mean a written request from POINT to CPDC authorizing the manufacture of one or more Batches, each
with a given number of Units or Doses of the Product. The Production Order is jointly maintained by CPDC and POINT based on clinical
requirements tied to subject enrollment.
	 
	2.13.	 “Quality Agreement” shall mean the quality agreement entered into by the parties concurrently with this Agreement, with
regard to the quality and regulatory requirements of the manufacturing, storage and distribution of the Product.
	 
	2.14.	“Regulatory Authority” shall mean the United States Food and Drug Administration (“FDA”), European Medicines
Agency (“EMA”), Health Canada and/or any other governmental, regulatory or administrative body having jurisdiction over any
activities conducted under this Agreement.
	 
	2.15.	“Specifications” shall mean the standards established in writing by the Parties for the characteristics, quality, and quality
control testing of Product, and its constituents, components, and packaging, as further described in Section 4.4 below.
	 
	2.16.	“Sub-total Labour Fees” shall mean the portion of the Total Batch Production Fee that is comprised of the fees for manufacturing,
QC testing and supervision, as defined in Schedule 1.
	 
	2.17.	 “Total Batch Production Fee” shall mean to the total between the Sub-total Labour Fees and the Batch Material, as defined
in Schedule 1.
	 
	2.18.	 “Unit” shall refer to an individual vial of Product produced according to the approved specifications.
	 	 
	3.  	Manufacture and Supply of Product

 

	3.1.	Scope and Object; Engagement. This Supply Agreement
    governs Clinical Phase supply for the Product in connection with Clinical Trials for which POINT supplies the product, and in accordance
    with the responsibilities and obligations attributed to each of the Parties as set out in this Supply Agreement. Accordingly, POINT
    hereby engages CPDC, and CPDC hereby accepts such engagement, to supply Product in connection with POINT’s supply for Clinical
    Trials. The Product shall be manufactured by CPDC in its cGMP facilities in the Tandem Accelerator Building (TAB) on the campus of
    McMaster University in Hamilton, Ontario, Canada, established for this purpose pursuant to Deliverables defined within the Supply
    Agreement. For the avoidance of doubt, it shall be the responsibility of POINT or its designate to file, obtain and maintain any
    Clinical Trial Application (CTA), Investigational New Drug (IND) or Investigational Medicinal Product Dossier (IMPD) applications
    as the case may be, registrations, listings, authorizations and approvals, as the Regulatory Authority may require to enable use
    of Product in Clinical Trials, and provide CPDC with all necessary particulars thereof and developments thereunder for each jurisdiction
    in which POINT will be performing the Clinical Trials.
	 	 
	3.2.	Production Orders. During the Term, set forth in
    Section 6 of this Supply Agreement, POINT and CPDC will agree to binding Production Orders for the Product, as follows:

 

	 	(a)	To facilitate planning and resourcing, POINT and CPDC shall agree to a nonbinding quarterly production forecast (the “Production
Forecast”) immediately following the entry into force of this Supply Agreement, and at the beginning of each Calendar Quarter.
This schedule shall be reviewed and updated from time to time for which the Parties may mutually agree on any adjustments to the Production
Forecast.

 

	Page 2 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

		(b)	Upon
the Commencement Date, POINT shall commit to a minimum annual total purchase commitment of [***] per year (the “Minimum Commitment”).
Such Minimum Commitment shall be reduced in the proportion of the Product that CPDC is unable to supply (as per Section 3.4) or that are
delivered and found nonconforming or defective (as per Section 3.8). In return CPDC shall commit to providing a minimum of [***] of Product
per Calendar Quarter in accordance with the provisions of this Section 3.2.

 

		(c)	In the event that the Minimum Commitment is not met, CPDC shall reserve the right to invoice POINT the
difference between the actual purchases and Minimum Commitment within 30 days following each yearly anniversary following the Commencement
Date. Upon Termination, the Minimum Commitment will be calculated proportionally from the Commencement Date anniversary of the year Termination
occurs until the date of Termination.

 

		(d)	CPDC shall confirm, by email, the acceptance of each Production Order typically within [***] business
day but no later than [***] business days of receipt of such Production Order (“Accepted Order”).

 

		(e)	POINT may make changes to an Accepted Order, including quantities ordered (when possible based on the
activity ordered) and delivery dates (a “Change Order”), or may terminate in whole or in part an Accepted Order (a “Termination
Order”) provided that such changes or termination is submitted in writing by email at least [***] business days prior to manufacture.
Confirmation of a Change Order or Termination Order will follow the same timeline as in Section 3.2 d. Any Change Order submitted within
[***] business days prior to manufacture may, at the sole discretion of CPDC, be accepted.

 

		(f)	Upon delivery or deemed delivery of any Termination Order:

 

		(i)	in the event that the Termination Order is delivered by POINT before [***] business days prior to the
date of manufacturing, CPDC shall be entitled to invoice POINT (in accordance with Section 3.5) for all unavoidable costs and out-of-pocket
expenses incurred and otherwise recoverable pursuant to Section 3.5.

 

		(ii)	in the event that the Termination Order is delivered by POINT within [***] to [***] business days prior
to the date of manufacturing, CPDC shall be entitled to invoice POINT (in accordance with Section 3.5) for all unavoidable costs and out-of-pocket
expenses incurred and otherwise recoverable pursuant to Section 3.5, plus [***] of the “Subtotal Labour Fees” which would
have otherwise been charged for such Production Order pursuant to Schedule 1 and Section 3.5.

 

		(iii)	in the event that the Termination Order is delivered by POINT within [***] to [***] business days prior
to the date of manufacturing, CPDC shall be entitled to invoice POINT (in accordance with Section 3.5) for all unavoidable costs and out-of-pocket
expenses incurred and otherwise recoverable pursuant to Section 3.5, plus [***] of the “Sub-total Labour Fees” and of the
 “Logistics and Distribution Fees” which would have otherwise been charged for such Production Order pursuant to Schedule 1
and Section 3.5.

 

		(iv)	in the event that the Termination Order is delivered by POINT on [***], CPDC shall be entitled to invoice
POINT (in accordance with Section 3.5) for all unavoidable costs and out-of-pocket expenses incurred and otherwise recoverable pursuant
to Section 3.5, plus
[***] of the “Total Batch Production Fee”, the “Dispensing Fees” and “Logistics and Distribution Fees”
which would have otherwise been charged for such Production Order pursuant to Schedule 1 and Section 3.5.

 

	Page 3 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

	 	(g)	In the event of a batch failure, POINT shall not be liable for payment of the fees specified in Schedule 1, and any such fees paid shall
be credited against the Minimum Production Commitment.

 

	3.3.	Shipping: All sales and deliveries of Product shall
    be Free Carrier shipping point (Incoterms-FCA 2010). For greater certainty, POINT shall take ownership of and bear all risk of loss
    of or damage to the Product at the origin of the shipment, unless the loss or damage is a direct results of an error or omission
    from CPDC.

 

		(a)	If requested, at POINT’s cost and expense, CPDC shall arrange for any insurance desired by POINT
on shipments of Product, in amounts that POINT shall determine, and naming POINT as the loss payee.

 

		(b)	When shipping Product, CPDC shall comply with all applicable laws and regulations, including compliance
at its own expense with all legal requirements (including obtaining any necessary license or approval) for the export of such Product
from Canada.

 

		(c)	All costs and responsibility for return shipping of any Product (other than Product that was defective
at the time of shipment to a POINT directed-location) and/or reusable packaging for return shipping including but not limited to, lead
pots, cardboard boxes or foam inserts, and/or other materials, shall be borne by POINT. If requested, at POINT’s cost and expense,
CPDC shall assist with the logistics of such return.

 

		(d)	In the event that any Product packaging materials are returned for reuse from Clinical Trial sites, POINT
shall be responsible for transportation, disposal and/or replacement of any damaged, unusable or lost materials, if applicable.

 

	3.4.	Inability
    to Supply. Time is of the essence for the supply of the Product. In the event that it becomes apparent to CPDC at any time that
    it will be unable to fulfill any Production Order or a Production Order will be delivered late, then CPDC shall immediately notify
    POINT in writing of CPDC’s inability to meet such requirements for Product, along with a specific indication of the reasons
    for such a situation, the proposed remedial measures, the date such inability is expected to end. According to that information,
    POINT shall be free to cancel the Production Order that CPDC is unable to fulfil and POINT shall not be liable for payment of the
    fees specified in Schedule 1, except in the following circumstances, in which the cancellation charges described in section 3.2(e)
    shall apply: where the failure to or delay in supplying Products is (a) due to circumstances described in Section 12 (force majeure),
    or (b) in the case of delay, where, had the Production Order not been cancelled, the delay would not have resulted in delay in patient
    administration, delay in preclinical and/or Clinical Trials or other loss for POINT.
	 	 
	3.5.	Pricing and Payment
    Terms. Schedule 1 of this Supply Agreement details the pricing and payment terms for the Product. For all batch-related fees
    and supply of Product, CPDC shall invoice POINT monthly. CPDC shall send such invoices to:
	 	 
	 	POINT Biopharma
	 	22 St. Clair Ave. East
	 	Suite 1201, Toronto, ON M4T 2S3
	 	Email: michael.gottlieb@pointbiopharma.com

 

	Page 4 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

 

 

	 	POINT shall pay such invoice within thirty (30) days of receipt of the invoice in accordance with the Supply Agreement.
	 	 
	3.6.	Batch Testing. POINT
    shall have the right but not the obligation to conduct any Batch testing (at its own expense) or investigation it determines to be
    of value to determine compliance of Product with the Specifications and/or pursuant to any other standard imposed by law. A Batch
    shall be deemed to be acceptable if, upon testing, it meets the Specifications, relevant cGMP standards, all other applicable laws,
    rules and regulations (and any additional tests as agreed by the Parties). If either Party discovers that a Batch does not meet the
    Specifications, relevant cGMP standards or other applicable laws, rules or regulations, then the discovering Party shall promptly
    communicate with the other Party. All warranty obligations of CPDC with respect to a particular Batch shall cease and have no effect
    to the extent that any defect in such Batch arises from abuse, misuse, alteration, mishandling, improper storage or gross negligence
    by POINT or POINT’s employees, representatives, agents, suppliers or carriers, or defects in Precursor materials furnished
    by POINT which are used in the production of such Batch.
	 
	3.7.	Dispute Over Quality.
    In the event of a conflict regarding whether or not Product met the Specifications, cGMP standards or other applicable laws,
    rules or regulations, at the time of delivery, which CPDC and POINT are unable to resolve after a good faith attempt by both Parties
    to resolve such matter in a period of [***] days after the conflict arises, a sample of such Product shall be submitted by POINT
    or its designee to an independent laboratory reasonably acceptable to both Parties for testing and the test results obtained by such
    laboratory shall be final and controlling for purposes of this Agreement. In the event the independent laboratory test results indicate
    that the rejected Product in question met the Specifications, cGMP standards, and all other applicable laws, rules and regulations,
    then POINT shall pay all additional shipping and transportation costs incurred as a result of the conflict and shall accept and pay
    for the previously rejected Product in accordance with all applicable provisions hereunder.
	 	 
	3.8.	Non-Conforming Products.
    In the event it is settled pursuant to Section 3.6 or 3.7 that Product in question did not meet the Specifications, cGMP standards
    or other applicable laws, rules or regulations, CPDC shall replace such Product, including “Total Batch Production Fee”,
    the “Dispensing Fees” and “Logistics and Distribution Fees”, at no additional cost to POINT, except for the
    isotope, precursor and reference standard and the associated shipping cost.
	 	 
	3.9.	Reliability. Manufacturing
    reliability is essential to minimizing interruptions patient treatment cycles and clinical trial deviations. The cumulative manufacturing
    reliability threshold will be set as follows:
	 	 
	 	[***] batches [***] % (for the avoidance of doubt equal or
higher than [***]% successful runs) [***] batches [***] % (for the avoidance of doubt equal or higher than [***]% successful runs) [***]
batches [***]% (for the avoidance of doubt equal or higher than [***]% successful runs)
	 	 
	 	Should a batch fail while the manufacturing reliability is
below the set threshold, and the root cause of the failure is attributable to CPDC as determined by an investigation, a reduction of
[***] percent ([***]%) of the Batch Production Fees (including the relevant Unit Fees) shall apply to the next Batch Production Order
(single batch order). If CPDC fails more than [***] batches in a Calendar Quarter, then the Parties agree to discuss changes to the agreement
and may renegotiate in good faith an amendment to the terms and conditions set forth in this Supply Agreement to achieve conditions suitable
for POINT to complete its clinical trial.

 

	Page 5 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

	4.	Additional Obligations of the Parties
	 	 
	4.1.	Record Keeping, Inspection, etc. CPDC shall:

 

		(a)	conform to the provisions detailed within the Quality Agreement;

 

		(b)	make available for review by POINT or any Regulatory Authority, within a reasonable
time, all applicable manufacturing and quality control records relevant to CPDC’s performance hereunder, including development,
validation documentation, written investigations of any deviations from specified manufacturing, packaging, inspection, or testing processes,
but excluding or redacted to exclude any confidential or proprietary information not specifically relating to performance of this Agreement;

 

		(c)	once every other year, upon reasonable notice to CPDC and in a manner calculated
not to unreasonably interfere with CPDC’s conduct of business or endanger the safety of any of its personnel, allow POINT employees
or representatives, including those of any Regulatory Authority, to inspect, at no extra cost to POINT other than its own expense and
that of the Regulatory Authority and under CPDC supervision, the manufacturing, packaging, testing, quality control and storage facilities
and/or programs of CPDC which relate to the Product, including the entire process of manufacture, packaging and storage of Product;

 

		(d)	to the extent CPDC is aware, promptly inform POINT, within [***] business days,
of any actual or threatened legal or regulatory action by any regulatory authority or governmental agency with respect to, the CPDC facilities
or operations relevant to the Product or the facilities or operations of any raw material suppliers used by CPDC for the manufacture of
Product (the “Facility”), and any other storage facilities of CPDC or its contractors for storage of Product, and promptly
provide POINT with access to any documentation resulting therefrom, and POINT will be consulted concerning any matters that could cause
a delay in Product production;
	 	 	 

		(e)	generate, store, ship and dispose of all waste associated with the manufacture
of Product in accordance with all applicable laws and regulations; and

 

		(f)	keep accurate financial records of all Services performed under this Supply Agreement
and all amounts to be invoiced to POINT and all invoice calculations, and, upon request by POINT, make such records available for review
by POINT or its representatives to permit verification of the correctness of such amounts and calculations.

 

	4.2.	Licenses and Permits. CPDC shall be responsible
    for obtaining and maintaining any and all facility or other licenses, permits, registrations, and any regulatory approvals necessary
    to manufacture, handle, store, label, package and prepare under cGMP conditions Product for shipment, and the packaging, supply and
    export of Product to POINT or its designees in accordance with the terms and conditions of this Agreement for the Clinical Phase.
    This includes, but is not limited to, the use and handling of radioactive materials. For greater certainty CPDC will abide by all
    laws, rules and regulations as applicable for radiation safety by the Canadian Nuclear Safety Commission (“CNSC”) for
    compliance.
	 	 
	4.3.	Precursor and Reference Standards. CPDC shall order
    the Precursor and reference standards from a supplier designated by POINT and in quantity agreed upon by POINT. CPDC will order the
    Precursor and reference standards in sufficient quantities to permit CPDC to meet its Production Forecast obligations hereunder.
    POINT’s designated supplier will provide Presursor and reference standards which meet the Specifications and shall provide
    to CPDC all required supporting documentation required for its use in manufacturing the Product, as required under GMP guideliines.
    In the event that the Precursor supplied by POINT’s designated supplier is found to be adulterated, damaged, or with compromised
    packaging, or not shipped within the required environmental conditions, CPDC shall return the Precursor to POINT’s designated
    supplier at POINT’s cost. CPDC shall only use Precursor and reference standards provided hereunder for the development, validation
    or manufacture of Products pursuant to this Agreement. POINT shall at all times retain title in and to such Precursor and reference
    standard materials in CPDC’s possession. POINT represents and warrants to CPDC that it has to its best knowledge all requisite
    rights and intellectual property in such Precursor and reference standard so as to permit their use by CPDC as contemplated by this
    Agreement without infringement of any third party rights. Upon expiration or termination of this Supply Agreement, CPDC shall return
    all unused Precursor materials provided by POINT’s designated supplier to POINT or its designee at POINT’s cost and expense.

 

	Page 6 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

	4.4.	Product Specifications: It
    is understood that the Specifications may be subject to change from time-to-time based on written agreement by both Parties and in
    accordance to the Quality Agreement. The Product Specifications may be referred to as the most recent approved version of the controlled
    document QC-SPEC-0139 as per CPDC quality system..
	 	 
	4.5.	Changes by CPDC. CPDC shall manufacture all Product
    in compliance with the Specifications, applicable cGMPs, the Quality Agreement, and all applicable laws, rules and regulations, and
    shall not make any changes contravening that specified within the Quality Agreement.
	 	 
	4.6.	Government Inspections, Compliance Review and Inquiries.
    As it pertains directly to the Product produced under this Agreement, upon request of any Regulatory Authority or any third party
    entity authorized by a Regulatory Authority, such entity shall, for the purpose of regulatory review, have access to observe and
    inspect the (i) Facility, (ii) procedures used for the storage of reference standards, Precursor and excipients, and (iii) manufacturing,
    testing, storage and preparation for shipment of Product, including Process development operations, and auditing the Facility for
    compliance with cGMP and/or other applicable regulatory standards. As it pertains directly to the Product under this Supply Agreement,
    CPDC shall give POINT prompt written notice of upcoming inspections or audits by a Regulatory Authority of the Facility or any of
    the foregoing and shall allow POINT, at its own expense and subject to the terms set out in Section 4.1(c), to participate in such
    audits by being present at any close-out meeting or similar regulatory inspection meeting and shall provide POINT with a written
    summary of such inspection or audit following completion thereof, together with all reports and/or warning letters (including without
    limitation any Form 483 from the FDA) received from the Regulatory Authority. Findings from government inspections that occur, which
    do not directly pertain to the Product, but may have impact on the Product or the manufacturing process will be communicated to POINT
    within [***] business days of receipt by CPDC. Notwithstanding the foregoing, POINT shall be entitled to have a representative in
    attendance at the Facility as an observer for the pre-approval inspection for the Product, at its own expense and subject to the
    terms set out in Section 4.1(c). CPDC agrees to use commercially reasonable efforts promptly to rectify or resolve any deficiencies
    noted by a Regulatory Authority in any such report or correspondence issued to CPDC. Subject to any specific arrangements agreed
    upon by the Parties, POINT shall be responsible for communicating with any Regulatory Authority concerning the Product or the use,
    marketing, distribution or sale of Product, and CPDC shall provide POINT with whatever assistance POINT may reasonably require to
    assist in such communications. CPDC shall have no such communications specifically related to Product, except as required by law
    to the extent that they relate to CPDC’s manufacturing activities under this Agreement, in which case CPDC shall be responsible
    for such communications. Notwithstanding the foregoing and except to the extent that an immediate communication is necessary under
    the circumstances or required by law, CPDC in good faith shall make reasonable efforts to consult in advance with POINT regarding
    all communications with Regulatory Authorities that relate to Product or to CPDC’s ability to manufacture Product pursuant
    to this Agreement, and shall provide POINT with a copy of any such communications at the time the communication is made or received.

 

	Page 7 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

	4.7.	Complaints and Adverse Reactions. CPDC or POINT
    shall provide to each other prompt notice of any information either Party receives regarding the safety of the Precursor, reference
    standards, excipients, Product or isotopes, including any confirmed or unconfirmed information regarding adverse, serious or unexpected
    events associated with any product that may implicate the manufacture of the Product or one of its components; provided, however,
    that POINT shall not be required to provide Clinical Trial reporting to CPDC. For all complaints with respect to the Product of which
    a Party becomes aware concerning adverse reactions or safety issues, notice must be given by telephone within [***] business day
    after receipt of the information, followed immediately with written notice, advising the other Party, regardless of the origin of
    such information. Any other complaints shall be reported in writing to the other party on a [***] basis. CPDC agrees to co-operate
    with POINT and any Regulatory Authority in evaluating any complaint, claim, safety or adverse use report related to the Product.
    CPDC will provide timely assistance in responding to any such complaints, including reviews of Batch records and retained samples
    as well as any necessary testing within reason.
	 	 
	4.8.	Recalls. POINT shall notify CPDC promptly if the
    Product is the subject of a recall or correction (a “Recall”), and POINT and/or its designee shall have sole responsibility
    for the handling and disposition of such Recall. POINT and/or its designee shall bear the costs of any Recall of a Product unless
    and to the extent such Recall shall have been the result of CPDC’s or its agents or employees acts or omissions or any product
    defects for which CPDC is responsible in which case CPDC shall to such extent be responsible for POINT’s reasonable out-of-pocket
    costs incurred including: notification of recall to CPDC and third parties; return shipment of any defective Product to CPDC; and
    replacement of Product, except for the isotope and the associated shipping cost.

 

		(a)	In the event that CPDC disputes POINT’s determination that the fault is due
to CPDC and/or to its employees or agents, the Parties will select a mutually agreeable outside consulting firm which will be instructed
to review the applicable information and data and to confirm or dissent from POINT’s determination. If the consulting firm confirms
POINT’s determination, CPDC will pay the fees of such consulting firm. If the consulting firm dissents from POINT’s determination,
CPDC will not have the obligations set forth herein with respect to the Recall and POINT will pay the fees of such consulting firm.

 

		(b)	POINT and/or its designee shall maintain records of all sales, shipping records
of Product and customers in sufficient detail to adequately administer a Recall for the period of time as required by applicable law and
regulation.

 

	4.9.	New Regulatory Requirements. Each Party shall promptly
    notify the other of new regulatory requirements of which it becomes aware which are relevant to the manufacture of the Product under
    this Agreement and which are required by the Regulatory Authorities, as applicable. The Parties shall confer with each other with
    respect to the best means to implement and comply with such requirements. Any reasonable costs for modifications or additions to
    the facility required as a result of new regulatory requirements shall be borne by POINT to the extent such modifications or additions
    directly relate to the manufacture of the Product; provided that the scope, and cost thereof shall have been preapproved in writing
    by POINT.
	 	 
	4.10.	Records. CPDC shall maintain all records necessary
    to evidence compliance in all respects with (i) the applicable cGMP regulations, Canadian Environmental Health and Safety (“EHS”)
    regulations, the requirements of the CNSC for handling of radioactive materials and the Canadian and International regulations for
    the transport of dangerous goods as related to the supply and manufacture of Product; (ii) the Specifications; and (iii) obligations
    under this Agreement. All such records shall be maintained by CPDC according to that specified within the Quality Agreement. CPDC
    shall provide to POINT reasonable access to such records upon request. Prior to destruction of any record after such time, CPDC shall
    give written notice to POINT. POINT shall have the right within [***] days of receipt of such notice to request that CPDC maintain
    such records in an off-site storage facility for such longer periods as POINT requests, provided that POINT pays all costs associated
    with such off-site storage.

 

	Page 8 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

      

 

	5.	Representations and Warranties
	 	 
	5.1.	Limited Product Warranty. CPDC hereby provides a
    limited product warranty, and accordingly does warrant for each Batch, that the Product shipped will (i) conform with the Specifications,
    (ii) be manufactured, tested, processed, packed and prepared for shipment in accordance with cGMPs, and (iii) be free from defects
    in material and workmanship for the period from the date of manufacture to the expiry date set out on each Unit of Product packed
    and prepared for shipment.
	 	 
	5.2.	No Implied or Other Warranties. CPDC is manufacturing
    Batches to meet Specifications and is supplying Product to POINT’s designees. Except as expressly set out in this Agreement,
    CPDC and POINT hereby disclaim all other warranties or conditions, whether express or implied, statutory or otherwise including,
    but not limited to, any implied warranties or conditions of merchantability or fitness for a particular purpose.
	 	 
	6.	 Term
	 
	6.1.	Term. This Supply Agreement shall commence on the
    Effective Date, and shall continue for a period of three (3) years, unless terminated earlier in accordance with the terms of this
    Supply Agreement (the “Initial Term”).
	 
	6.2.	Term, Renewal. Following the Initial Term, this
    Supply Agreement shall automatically renew for successive periods of one (1) year (each a “Renewal Term”), unless
    a Party delivers written notice of non-renewal to the other Party at least three (3) months prior to the end of the applicable term.
    The Initial Term and Renewal Terms shall be collectively referred to as the “Term”.
	 
	7.	 Termination
	 	 
	7.1.	Termination by POINT, Without Cause. Following the
    first anniversary of the Commencement Date POINT may terminate this Agreement without cause with six (6) months’ written notice
    to CPDC.
	 	 
	7.2.	Termination by POINT, For Cause. POINT may terminate
    this Agreement with immediate effect, by providing written notice to the CPDC, where:

 

		(a)	CPDC commits a material breach of any of its obligations under this Supply Agreement,
and such breach is not remedied (if capable of remedy) within [***] calendar days of notice in writing by POINT requiring that such breach
be remedied;

 

		(b)	CPDC becomes insolvent or goes into administration, receivership or liquidation
or enters into any arrangement or composition with its creditors; or

 

		(c)	CPDC ceases or threatens to cease carrying on business, on a non-temporary basis
or longer than 6 months.
	 	 	 
	 	d)	If
CPDC is no longer able to perfom its obligation under this agreement

 

	Page 9 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

	7.3.	Termination by CPDC, For Cause. CPDC may terminate this Agreement immediately
    on written notice to POINT if:

 

		(a)	POINT fails to
pay or dispute any invoice in accordance with section 3.5 and fails to remedy such breach within [***] days of a notice from CPDC requiring
POINT to remedy the same and stipulating that POINT is in breach of this Agreement; or

 

		(b)	POINT becomes insolvent or goes into administration, receivership or liquidation
or enters into any arrangement or composition with its creditors.

 

	7.4.	Termination of this Agreement is without prejudice to any accrued rights of either party as at the date of termination, including, without
limitation, CPDC’s right to invoice POINT pursuant to Section 3.5 for any amounts chargeable pursuant to this Agreement as of the
date of termination.
	 	 
	7.5.	Upon termination of this Supply Agreement for any reason whatsoever:

 

		(a)	CPDC must immediately return, at POINT’s expense, all of POINT’s property in CPDC’s
possession; and

 

		(b)	all then active Production Orders shall be deemed to have been subject to Termination
Orders as per Section 3.2 (f), as of the effective date of termination of this Agreement.

 

	7.6.	Prior Obligations. Except as otherwise set forth
    in this Section 7, termination of this Supply Agreement for any reason shall not release either Party from any obligation theretofore
    accrued.
	 	 
	8.	 Remedies and Indemnities
	 	 
	8.1.	Limitation of Liability. Under no circumstances
    whatsoever shall either Party be liable to the other in contract, tort, negligence, breach of statutory duty or otherwise for (i)
    any (direct or indirect) loss of profits, of production, of anticipated savings, of business or goodwill, or (ii) for any other liability,
    damage, costs or expense of any kind incurred by the other Party of an indirect or consequential nature, regardless of any notice
    of the possibility of such damages.
	 	 
	8.2.	Limitation of Liability.

 

		(a)	Maximum Liability. Either Party’s maximum liability to the other Party under
this Supply Agreement for any reason whatsoever, including, without limitation, any liability resulting from any and all breaches of its
representations, warranties, or any other obligations under this Agreement will not exceed [***]% of the total service fees paid to CPDC
(excluding all pass-through fees for materials and out-of-pocket costs) under this Supply Agreement in the calendar year in which the
claim arose.

 

		(b)	Death, Personal Injury and Fraudulent Misrepresentation. Nothing contained in this
Agreement shall act to exclude or limit either Party’s liability for personal injury, death or fraudulent misrepresentation caused
by the negligence of either Party.

 

	Page 10 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

 

 

	8.3.	Indemnification by CPDC.

 

	 	(a)	 Subject to Sections 8.1 and 8.2, CPDC agrees to defend, indemnify and hold POINT and its officers, employees and agents, harmless against
any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than affiliates)
resulting from, or relating to any claim of personal injury or property damage to the extent that such injury or damage is the result
of a failure by CPDC to manufacture Product in accordance with the Specifications, cGMPs and applicable laws except to the extent that
any such losses, damages, costs, claims, demands, judgments and liability are due to the negligence or wrongful act(s) of POINT or its
officers, employees or agents or affiliates.
	 
	 	(b)	 In the event of a claim pursuant to Section 8.3(a), POINT shall: (i) promptly notify CPDC of any such claim; (ii) use commercially reasonable
efforts to mitigate the effects of such claim; (iii) reasonably cooperate with CPDC in the defence of such claim; (iv) permit CPDC to
control the defence and settlement of such claim, all at CPDC’s cost and expense, provided CPDC’s consent shall be required
for any final settlement of such claim.

 

	8.4.	Indemnification by POINT.

 

		(a)	Subject to Sections 8.1 and 8.2, POINT agrees to defend, indemnify and hold CPDC
and its affiliates their respective officers, employees and agents harmless against any and all losses, damages, costs, claims, demands,
judgments and liability to, from and in favour of third parties (other than affiliates) resulting from, or relating to any claim of infringement
or alleged infringement of any intellectual property rights of any third party in respect of the Product, or any portion thereof, and/or
any claim of personal injury or property damage to the extent that such injury or damage is the result of a breach of this Agreement by
POINT, including, without limitation, any representation or warranty contained herein, or any negligence or wrongful act(s) of POINT or
its officers, employees or agents in the handling, storage, distribution or use of Product after taking possession from CPDC, except to
the extent that any such losses, damages, costs, claims, demands, judgments and liability are due to the negligence or wrongful act(s)
of CPDC or its officers, employees or agents.
	 	 	 

		(b)	In the event of a claim pursuant to Section 8.4(a), CPDC shall: (i) promptly notify
POINT of any such claims; (ii) use commercially reasonable efforts to mitigate the effects of such claim; (iii) reasonably cooperate with
POINT in the defence of such claim; (iv) permit POINT to control the defence and settlement of such claim, all at POINT’s cost and
expense, provided POINT’s consent shall be required for any final settlement of such claim.

 

	9.	Survival. Any provision of this Supply Agreement, which, by its terms,
    is capable of surviving the termination or expiration of this Supply Agreement, shall survive such termination or expiration of this
    Agreement.
	 	 
	10.	Assignment. This Agreement shall inure to the benefit of and be binding
    upon the successors and assigns of the Parties hereto; provided, however, that neither Party shall transfer or assign this Agreement
    without the prior written consent of the other Party, such consent not to be unreasonably withheld, except where such assignment
    is by CPDC to any successor or subsidiary organization created within 36 months of the Effective Date of this Agreement, which assignment
    may be completed without the prior written consent of POINT. Notwithstanding the foregoing, each Party may assign this Agreement
    and its rights and obligations hereunder without such consent in connection with the transfer or sale of all or substantially all
    of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise, provided
    the assignee agrees in writing with the other Party hereto to assume all obligations and liabilities of the assignor under this Agreement.

 

	Page 11 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

 

 

	11.	Commercial Supply. POINT hereby grants to CPDC the Right of First
    Offer (“ROFO”) to [***].
	 	 
	12. 	Force Majeure. Each
    Party shall be excused from delays in performing or from its failure to perform its obligations under this Agreement to the extent
    that such delays or failures result from any of the following events or circumstances, such that no Party may terminate this
    Agreement and the non-performing Party shall not be in breach of this Agreement until the cause of such delay or failure is
    resolved, provided such non-performing Party acts diligently to remedy the cause of such delay or failure to the extent possible
    and, upon cessation of such cause, as soon as reasonably possible perform all obligations it would have been obligated to have
    performed by such time but for such cause:

 

		(a)	any cause affecting the performance of this Agreement arising from or attributable
to any acts, events, non-happenings, omissions or accidents beyond the reasonable control of the Party to perform and in particular but
without limiting the generality thereof shall include strikes, lock outs, industrial action, action or inaction of any regulatory authority,
civil commotion, riot, invasion, war, threat of or preparation for war, terrorist activity, fire, explosion, storm, flood, earthquake,
subsidence, epidemic or other natural physical disaster, impossibility of the use of railways, shipping, aircraft, motor transport, or
other means of public or private transport, failure or suspension of utilities, and political interference with the normal operation of
either Party; or

 

		(b)	delays or interference with the performance of the non-performing Party’s
obligations under this agreement resulting from the acts or omissions of the other Party, or any other persons acting under the direction
or control of the such other Party.

 

	13.	Use of Names.
    Neither Party has the right to use the other Party’s name, trademarks or other identifying marks or intellectually property,
    or the names of the other Party’s employees, in any advertising, sales promotional material or press release without the prior
    written permission of the other Party, except to the extent such disclosure is reasonably necessary for regulatory filings, prosecuting
    or defending litigation, and complying with applicable governmental regulations and legal requirements and the requirements of any
    stock exchange or stock listing entity.
	 	 
	14.	Notices. Any notice or other communication required
    or permitted to be given hereunder shall be in writing and shall be delivered in person, transmitted by facsimile, e-mail or similar
    means of recorded electronic communication or sent by registered mail, charges prepaid, addressed to the addresses set out on the
    signature page hereof. Any such notice or other communication shall be deemed to have been given and received on the day on which
    it was delivered or transmitted (or, if such day is not a business day, on the next following business day) unless mailed, in which
    case on the third (3rd) business day following the date of mailing; provided, however, that if at the time of mailing or within three
    (3) business days thereafter there is or occurs a labour dispute or other event that might reasonably be expected to disrupt the
    delivery of documents by mail, any notice or other communication hereunder shall be delivered or transmitted by means of recorded
    electronic communication as described.
	 	 
	15.	Severability. Each provision contained in this Agreement
    is distinct and severable and a declaration of invalidity or unenforceability of any such provision or part thereof by a court of
    competent jurisdiction shall not affect the validity or enforceability of any other provision hereof.
	 	 
	16.	Entire Agreement. This Agreement, including all
    schedules hereto, constitutes the entire agreement between the Parties with respect to the subject matter (such that there are no
    conditions, covenants, agreements, representations, warranties or other provisions, express or implied, collateral, statutory or
    otherwise, relating to the subject matter except provided in this Agreement) and supersedes all prior agreements, understandings,
    negotiations and discussions, whether written or oral.

 

	Page 12 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

	17.	Number, Gender and Persons. Unless the context otherwise requires, any
    reference to gender shall include both genders and words importing the singular number shall include the plural and vice-versa. Words
    importing “persons” include individuals, partnerships, associations, trusts, unincorporated organizations and corporations.
	 	 
	18.	Headings and References. The division of this Agreement into Sections,
    subsections and further divisions, and the insertion of headings are for convenience of reference only and do not affect the construction
    or interpretation of this Agreement. The terms “this Agreement”, “hereof”, “hereunder” and similar
    expressions refer to this Agreement and not to any particular Sections, subsection or other portion hereof, and include any agreement
    supplemental hereto. Unless something in the subject matter or context is inconsistent therewith, references herein to Sections,
    subsections, paragraphs, subparagraphs and further subdivisions are references to such subdivisions of this Agreement.
	     	 
	19.	Calculation of Time Periods. Where a time period is expressed to begin
    or end at, on or with a specified day, or to continue to or until a specified day, the time period includes that day. Where a time
    period is expressed to begin after or to be from a specified day, the time period does not include that day. Where anything is to
    be done within a time period expressed after, from or before a specified day, the time period does not include that day. If the last
    day of a time period is not a business day, the time period shall end on the next business day.
	     	 
	20.	Definitions. Any definitions contained in this Agreement shall include
    any necessarily corresponding definitions as the context may require. Any capitalized or otherwise defined term used in this Agreement
    shall have the meaning ascribed in this Agreement regardless of whether such meaning is ascribed earlier or later in this document
    than the reference in question.
	     	 
	21.	Further Assurances. Each of the Parties hereto shall, at all times and
    from time to time hereafter, execute, acknowledge, and deliver such other instruments and shall take such other action as may be
    necessary to carry out their respective obligations under this Agreement.
	     	 
	22.	Waiver. Except as expressly provided in this Agreement, no amendment
    or waiver of this Agreement or any portion thereof shall be binding unless executed in writing. No waiver of any provision of this
    Agreement shall constitute a waiver of any other provision, nor shall any waiver of any provision of this Agreement constitute a
    continuing waiver unless otherwise expressly provided.
	     	 
	23.	Counterparts. This Agreement may be executed in any number of counterparts,
    and/or by facsimile or e-mail transmission of standard PDF files, each of which shall constitute an original and all of which, taken
    together, shall constitute one and the same instrument.

 

(remainder of page intentionally left blank;
signature page follows)

 

	Page 13 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit. 

     

     

    

 

 

 

	 	Supply
    Agreement – Lu-177-PNT2002

 

 

IN
WITNESS WHEREOF, the Parties hereto have each caused this Supply Agreement to be duly executed as of the Effective Date.

 

	
    Centre for Probe Development and

    Commercialization

    McMaster University

    Nuclear Research Building, A316

    1280 Main Street West

    Hamilton, Ontario

    Canada, L8S 4K1 
	
    POINT Biopharma Corporation

    22 St. Clair Ave. East

    Suite 1201

    Toronto, Ontario

    Canada, M4T 2S3 

 

	By	/s/
    Justyna Kelly	 	By	/s/
    Joe McCann
	Name   	Justyna Kelly	 	Name   	Joe
    McCann
	Title	CEO	 	Title	CEO
	Date	2020/07/12	 	Date	2020- 07- 12

 

[SIGNATURE PAGE]

 

	Page 14 of 14	CONFIDENTIAL
	 	 
	[***] = Indicates confidential information omitted from the exhibit.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]